DURHAM, N.C., MAY 23, 2017 — Interleukin-2, interferon, and other immune-modulating agents have long been used to treat some solid malignancies, but their efficacy is generally limited to immunogenic cancers such as melanoma and kidney cancer. Until now.
Today, multiple immuno-oncology pathways are under development, and we’ll explore this promising trend in a webinar on Wednesday, May 23, at 11 a.m. EDT / 4 p.m. BST / 5 p.m. CEST. Expanding the Potential of Immuno-Oncology Therapies will examine the growing role of immuno-oncology drugs such as checkpoint inhibitors, antibody drug conjugates, autologous cellular immunotherapy, and oncolytic viruses.
The recording is now available to learn more.
About Premier Research
Premier Research is a leading clinical development service provider that helps highly innovative biotech and specialty pharma companies transform breakthrough ideas into reality. The company has a wealth of experience in the execution of global, regional and local clinical development programs with a special focus on addressing unmet needs in areas such as analgesia, dermatology, medical device, neuroscience, oncology, pediatric, and rare disease. Premier Research operates in 84 countries and employs 1,000 professionals, including a strong international network of clinical monitors and project managers, regulatory, data management, statistical, scientific, and medical experts. They are focused on smart study design for advanced medicines that allow life-changing treatments.